The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

By Michael Erman and Mariam Sunny (Reuters) -Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak discretionary spending, a ...

Pause on Gardasil China sales from Feb to at least mid-2025 Keytruda beats, Gardasil misses Q4 sales estimates Merck pulls Gardasil's long-term sales target Shares tumble 11% in early trading Feb ...

Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The pharmaceutical giant’s CEO mentioned this in the Q4 earnings call ...

The pause announcement comes a month after Merck received approval in China for use of the vaccine in males. “We believe China still represents a significant, long-term opportunity for Gardasil ...

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.

(Reuters) -Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak discretionary spending, a move that dented its full-year ...

The drugmaker plans to temporarily pause shipments of its Gardasil vaccine to China through at least the middle of the year. Merck gave no explanation in its fourth-quarter earnings report for the ...

Merck, which makes the commonly used Gardasil shot, has shed 14 per cent of its market value since announcing last week that it expects to sell less of its human papillomavirus vaccine in China ...